Abcam (ABCM) Stock Price, News & Analysis $23.99 +0.01 (+0.04%) (As of 12/5/2023) Add Compare Share Share Today's Range$23.98▼$24.0050-Day Range$22.61▼$23.9952-Week Range$12.48▼$25.32Volume7.43 million shsAverage Volume3.08 million shsMarket Capitalization$5.50 billionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Abcam MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside4.1% Downside$23.00 Price TargetShort InterestHealthy2.43% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth29.55%From $0.44 to $0.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.52 out of 5 starsMedical Sector856th out of 942 stocksBiotechnology Industry31st out of 41 stocks 1.1 Analyst's Opinion Consensus RatingAbcam has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Abcam has a forecasted downside of 4.1% from its current price of $23.99.Amount of Analyst CoverageAbcam has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.43% of the outstanding shares of Abcam have been sold short.Short Interest Ratio / Days to CoverAbcam has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abcam has recently increased by 36.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbcam does not currently pay a dividend.Dividend GrowthAbcam does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCM. Previous Next 2.0 News and Social Media Coverage News SentimentAbcam has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Abcam this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Abcam to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Abcam insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.73% of the stock of Abcam is held by insiders.Percentage Held by Institutions90.45% of the stock of Abcam is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Abcam are expected to grow by 29.55% in the coming year, from $0.44 to $0.57 per share.Price to Earnings Growth RatioAbcam has a PEG Ratio of 2.19. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAbcam has a P/B Ratio of 6.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Abcam Stock (NASDAQ:ABCM)Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.Read More ABCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCM Stock News HeadlinesDecember 8, 2023 | finance.yahoo.comAbcam plc (ABCM) Interactive Stock Chart - Yahoo FinanceDecember 6, 2023 | americanbankingnews.comAbcam plc (NASDAQ:ABCM) Receives Consensus Recommendation of "Hold" from AnalystsDecember 11, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 5, 2023 | americanbankingnews.comReviewing aTyr Pharma (NASDAQ:LIFE) & Abcam (NASDAQ:ABCM)November 17, 2023 | markets.businessinsider.comAbcam-Danaher Deal Receives All Identified Clearances - Quick FactsNovember 15, 2023 | finance.yahoo.comHere’s Headwaters Capital’s Perspective on Abcam plc (ABCM) AcquisitionNovember 6, 2023 | tmcnet.comShareholders of Abcam Approve Proposed Acquisition by DanaherNovember 1, 2023 | benzinga.comStatement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaignDecember 11, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 1, 2023 | finanznachrichten.deAbcam plc: Leading Proxy Advisor, ISS, Recommends Shareholders Vote "FOR" Danaher Corporation's Proposed Acquisition of AbcamOctober 23, 2023 | stockhouse.comLeading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote "FOR" Danaher Corporation's Proposed Acquisition of AbcamOctober 19, 2023 | finance.yahoo.comShe Blinded Me with Science – ISS Makes Schoolboy Error on Abcam DealOctober 17, 2023 | finance.yahoo.comLeading Proxy Advisor, ISS, Recommends Shareholders Vote "FOR" Danaher Corporation’s Proposed Acquisition of AbcamOctober 16, 2023 | markets.businessinsider.comJonathan Milner Issues Statement Responding to ISS ReportOctober 16, 2023 | msn.comAbcam holders should vote for sale to Danaher, proxy adviser ISS says (update)October 16, 2023 | finance.yahoo.comJonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the CompanyOctober 9, 2023 | markets.businessinsider.comAbcam (ABCM) Gets a Hold from RBC CapitalOctober 5, 2023 | msn.comGMED or ABCM: Which Is the Better Value Stock Right Now?October 5, 2023 | finanznachrichten.deAbcam plc: Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per ShareSeptember 21, 2023 | finance.yahoo.comHeadwaters Capital Calls Out Fishy Bid for Abcam from Danaher in Letter to Stakeholders – ExclusiveSeptember 15, 2023 | msn.comAbcam holder, founder Jonathan Milner opposes Danaher acquisition (update)September 14, 2023 | benzinga.comAbcam plc Statement on Dr. Jonathan Milner's AnnouncementSeptember 14, 2023 | msn.comAbcam holder, founder Jonathan Milner opposes Danaher acquisitionAugust 31, 2023 | finance.yahoo.comAbcam plc Interim Results for the Six-Month Period Ended 30 June 2023August 30, 2023 | msn.comAbcam cut to market perform at Leerink, sees no antitrust riskAugust 29, 2023 | msn.comAbcam deal price may have been hurt by antitrust concerns - report (update)August 29, 2023 | benzinga.comABCAM INVESTOR ALERT by the Former Attorney...See More Headlines Receive ABCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABCM CUSIPN/A CIK1492074 Webwww.abcam.com Phone44-0-12-2369-6000FaxN/AEmployees1,760Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$23.00 Low Stock Price Target$23.00 Potential Upside/Downside-4.1%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio54.52 P/E Growth2.19Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.00 Sales & Book Value Annual Sales$379.70 million Price / Sales14.49 Cash Flow$0.60 per share Price / Cash Flow40.17 Book Value$3.92 per share Price / Book6.12Miscellaneous Outstanding Shares229,272,000Free Float213,842,000Market Cap$5.50 billion OptionableNot Optionable Beta0.86 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Alan Thomas Hirzel BS (Age 55)M.B.A., M.S., CEO & Executive Director Comp: $1.18MMr. Michael Shaun Baldock B.A. (Age 59)CFO & Director Comp: $876.48kMarc Leigh Russell PerkinsGeneral Counsel & Company SecretaryEmma SceatsSenior Vice President of Sales & MarketingMr. Nick SkinnerSenior Vice President of Human ResourcesMs. Alejandra Solache Ph.D.Senior Vice President of Research & DevelopmentMr. John BakerSenior Vice President of Supply Chain & ManufacturingJuan Carlos SacristanSenior Vice President of Data & DigitalMore ExecutivesKey CompetitorsCRISPR TherapeuticsNASDAQ:CRSPHalozyme TherapeuticsNASDAQ:HALOImmunovantNASDAQ:IMVTVaxcyteNASDAQ:PCVXExelixisNASDAQ:EXELView All CompetitorsInstitutional OwnershipHudson Bay Capital Management LPBought 3,022,022 shares on 12/7/2023Ownership: 1.340%Citigroup Inc.Bought 231,334 shares on 12/6/2023Ownership: 0.105%Wellington Management Group LLPSold 9,051,360 shares on 12/1/2023Ownership: 2.024%American Century Companies Inc.Sold 180,676 shares on 11/30/2023Ownership: 0.057%Carmignac GestionBought 274,799 shares on 11/29/2023Ownership: 0.120%View All Institutional Transactions ABCM Stock Analysis - Frequently Asked Questions Should I buy or sell Abcam stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ABCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares. View ABCM analyst ratings or view top-rated stocks. What is Abcam's stock price target for 2024? 6 Wall Street analysts have issued 1-year target prices for Abcam's stock. Their ABCM share price targets range from $23.00 to $23.00. On average, they anticipate the company's stock price to reach $23.00 in the next twelve months. This suggests that the stock has a possible downside of 4.1%. View analysts price targets for ABCM or view top-rated stocks among Wall Street analysts. How have ABCM shares performed in 2023? Abcam's stock was trading at $15.56 at the start of the year. Since then, ABCM stock has increased by 54.2% and is now trading at $23.99. View the best growth stocks for 2023 here. Are investors shorting Abcam? Abcam saw a increase in short interest in November. As of November 15th, there was short interest totaling 5,580,000 shares, an increase of 36.8% from the October 31st total of 4,080,000 shares. Based on an average daily volume of 7,370,000 shares, the short-interest ratio is presently 0.8 days. View Abcam's Short Interest. What ETFs hold Abcam's stock? ETFs with the largest weight of Abcam (NASDAQ:ABCM) stock in their portfolio include BlackRock Future Health ETF (BMED), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).ProShares Ultra Nasdaq Biotechnology (BIB). When did Abcam IPO? (ABCM) raised $149 million in an initial public offering (IPO) on Thursday, October 22nd 2020. The company issued 9,000,000 shares at $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair served as the underwriters for the IPO. Who are Abcam's major shareholders? Abcam's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.19%), Soros Fund Management LLC (2.70%), JPMorgan Chase & Co. (2.64%), Brown Advisory Inc. (2.25%), KRYGER CAPITAL Ltd (2.04%) and Wellington Management Group LLP (2.02%). How do I buy shares of Abcam? Shares of ABCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ABCM) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abcam plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.